Health related quality of life in patients with critical limb ischemia;Lebensqualität bei patienten mit kritischer extremitäten -is chämie

Vasa - Journal of Vascular Diseases

Volumn 41, Issue 2, 2012, Pages 78-88

  Lawall, Holger ^a   Zemmrich, Claudia ^b   Bramlage, Peter ^b   Amann, Berthold ^a  

^a Asklepios Westklinikum Hamburg   (Germany)

^b Institut fur Pharmakologie und Praventive Medizin   (Germany)

Author keywords

Critical limb ischemia; Health related quality of life; Prostaglandin; SF 36

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; PROSTAGLANDIN E1; PROSTANOID;

ANTICOAGULANT THERAPY; BLEEDING; DISEASE COURSE; DISEASE SEVERITY; ENDARTERECTOMY; FOLLOW UP; HEMATOMA; HUMAN; HYPERBARIC OXYGEN; INFECTION; INTERMITTENT PNEUMATIC COMPRESSION DEVICE; LIMB ISCHEMIA; LUMBAR SYMPATHECTOMY; OUTCOME ASSESSMENT; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; QUALITY OF LIFE; QUESTIONNAIRE; REVASCULARIZATION; REVIEW; SPINAL CORD STIMULATION; TREATMENT DURATION;

ANGIOPLASTY, BALLOON; CARDIOVASCULAR AGENTS; CRITICAL ILLNESS; DISEASE PROGRESSION; EVIDENCE-BASED MEDICINE; HUMANS; ISCHEMIA; PREDICTIVE VALUE OF TESTS; PROSTAGLANDINS; QUALITY OF LIFE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; VASCULAR SURGICAL PROCEDURES;

EID: 84858597644     PISSN: 03011526     EISSN: None     Source Type: Journal    
DOI: 10.1024/0301-1526/a000169     Document Type: Review

References (67)

1. Euro Qol a new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy. 1990 Dec;16 [3]: 199-208.
2. Adam DJ, Beard JD, Cleveland T, Bell J, Bradbury AW, Forbes JF, Fowkes FG, Gillepsie I, Ruckley CV, Raab G, Storkey H. Bypass versus angioplasty in severe ischaemia of the leg [BASIL]: multicentre, randomised controlled trial. Lancet. 2005 Dec 3; 366 [9501]: 1925-34.
3. Albers M, Fratezi AC, De Luccia N. Assessment of quality of life of patients with severe ischemia as a result of infrainguinal arterial occlusive disease. J Vasc Surg. 1992 Jul; 16 [1]: 54-9.
4. Amann B, Ludemann C, Ruckert R, Lawall H, Liesenfeld B, Schneider M, Schmidt-Lucke J. Design and rationale of a randomized, double- blind, placebo-controlled phase III study for autologous bone marrow cell transplantation in critical limb ischemia: the BONe Marrow Out- comes Trial in Critical Limb Isch- emia [BONMOT-CLI]. Vasa. 2008 Nov; 37 [4]: 319-25.
5. Amann B, Luedemann C, Ratei R, Schmidt-Lucke JA. Autologous bone marrow cell transplantation increases leg perfusion and reduces amputations in patients with advanced critical limb ischemia due to peripheral artery disease. Cell Transplant. 2009; 18 [3]: 371-80.
6. Anderson RT, Aaronson NK, Wilkin D. Critical review of the international assessments of health-related quality of life. Qual Life Res. 1993 Dec; 2 [6]: 369-95.
7. Attanasio S, Snell J. Therapeutic angiogenesis in the management of critical limb ischemia: current concepts and review. Cardiol Rev. 2009 May-Jun; 17 [3]: 115-20.
8. Berceli SA, Hevelone ND, Lipsitz SR, Bandyk DF, Clowes AW, Moneta GL, Conte MS. Surgical and endovascular revision of infrainguinal vein bypass grafts: analysis of midterm outcomes from the PREVENT III trial. J Vasc Surg. 2007 Dec; 46 [6]: 1173-9.
9. Bullinger M, Cachovan M, Creutzig A, Diehm C, Gruss J, Heidrich H, Kirchberger I, Loeprecht H, Rogatti W. [Development of an illness-specific instrument for assessmentof quality of life in patients witharterial occlusive disease [Peripheral Arterial Occlusive Disease 86 Questionnaire]]. Vasa. 1996; 25 [1]: 32-40.
10. Burt RK, Testori A, Oyama Y, Rodriguez HE, Yaung K, Villa M, Bucha JM, Milanetti F, Sheehan J, Rajamannan N, Pearce WH. Au-dolorous peripheral blood CD133+ cell implantation for limb salvage in patients with critical limb ischemia. Bone Marrow Transplant. 2010 Jan; 45 [1]: 111-6.
11. Creutzig A. [Therapy of peripheral arterial occlusive disease with spe- cial reference to prostaglandins]. Z Gesamte Inn Med. 1991 Mar; 46 [3]: 59-67.
12. Creutzig A, Bullinger M, Cachovan M, Diehm C, Forst HT, Gruss JD, Horsch S, Rogatti W, Scheffler P, Spengel F, Stiegler H. Improvement in the quality of life after i.v. PGE1 therapy for intermittent claudication. Vasa. 1997 May; 26 [2]: 122-7.
13. Deutschmann HA, Schoellnast H, Temmel W, Deutschmann M, Schwantzer G, Fritz GA, Brodmann M, Hausegger KA. Endoluminal therapy in patients with peripheral arterial disease: prospective assessment of quality of life in 190 patients. AJR Am J Roentgenol. 2007 Jan; 188 [1]: 169-75.
14. Diehm C, Diehm N. Non-invasive treatment of critical limb ischemia. Curr Drug Targets Cardiovasc Haematol Disord. 2004 Sep; 4 [3]: 241-7.
15. Dormandy JA, Rutherford RB. Management of peripheral arterial disease [PAD]. TASC Working Group. TransAtlantic Inter-Society Consensus [TASC]. J Vasc Surg. 2000 Jan; 31 [1 Pt 2]:S1-S296.
16. Engelhardt M, Bruijnen H, Scharmer C, Jezdinsky N, Wolfle K. Improvement of quality of life six months after infrageniculate bypass surgery: diabetic patients benefit less than non-diabetic patients. Eur J Vasc Endovasc Surg. 2006 Aug; 32 [2]: 182-7.
17. Engelhardt M, Bruijnen H, Scharmer C, Wohlgemuth WA, Willy C, Wolfle KD. Prospective 2-years follow-up quality of life study after infrageniculate bypass surgery for limb salvage: lasting improvements only in non-diabetic patients. Eur J Vasc Endovasc Surg. 2008 Jul; 36 [1]: 63-70.
18. Forbes JF, Adam DJ, Bell J, Fowkes FG, Gillespie I, Raab GM, Ruckley CV, Bradbury AW. Bypass versus Angioplasty in Severe Ischaemia of the Leg [BASIL] trial: Health-related quality of life outcomes, resource utilization, and cost-effectiveness analysis. J Vasc Surg. 2010 May; 51 [5 Suppl]: 43S-51S.
19. Greiner W, Weijnen T, Nieuwen-huizen M, Oppe S, Badia X, Buss-chbach J, Buxton M, Dolan P, Kind P, Krabbe P, Ohinmaa A, Parkin D, Roset M, Sintonen H, Tsuchiya A, de Charro F. A single European currency for EQ-5D health states. Results from a six-country study. Eur J Health Econ. 2003 Sep; 4 [3]: 222-31.
20. Heidrich H, Bullinger M, Cachovan M, Creutzig A, Diehm C, Gruss JD, Kirchberger I, Loeprecht H, Rogatti W. [Quality of life in peripheral arterial occlusive disease. Multicenter study of quality of life characteristics with a newly developed disease-specific questionnaire]. Med Klin [Munich]. 1995 Dec 15; 90 [12]: 693-7.
21. Hernandez-Osma E, Cairols MA, Marti X, Barjau E, Riera S. Impact of treatment on the quality of life in patients with critical limb ischaemia. Eur J Vasc Endovasc Surg. 2002 Jun; 23 [6]: 491-4.
22. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, Hiratzka LF, Murphy WR, Olin JW, Puschett JB, Rosenfield KA, Sacks D, Stanley JC, Taylor LM, Jr., White CJ, White J, White RA, Ant- man EM, Smith SC, Jr., Adams CD, Anderson JL, Faxon DP, Fuster V, Gibbons RJ, Hunt SA, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B. ACC/AHA 2005. Practice Guidelines for the management of patients with peripheral arterial disease [lower extremity, renal, mesenteric, and abdominal aortic]: a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines [Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease]: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; Trans Atlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation. 2006 Mar 21; 113 [11]:e463-654.
23. Holler D, Claes C, von der Schulenburg JM. Treatment costs and quality of life of patients with peripheral arterial occlusive disease--the German perspective. Vasa. 2004 Aug; 33 [3]: 145-53.
24. Hunt SM, McEwen J, McKenna SP. Measuring health status: a new tool for clinicians and epidemiologists. J R Coll Gen Pract. 1985 Apr; 35 [273]: 185-8.
25. Kalbaugh CA, Taylor SM, Blackhurst DW, Dellinger MB, Trent EA, Youkey JR. One-year prospective quality-of-life outcomes in patients treated with angioplasty for symptomatic peripheral arterial disease. J Vasc Surg. 2006 Aug; 44 [2]: 296-302; discussion -3.
26. Kalbaugh CA, Taylor SM, Cull DL, Blackhurst DW, Gray BH, Langan EM, 3rd, Dellinger MB, McClary GE, Jr., Jackson MR, Carsten CG, 3rd, Snyder BA, York JW, Youkey JR. Invasive treatment of chronic limb ischemia according to the Lower Extremity Grading System [LEGS] score: a 6-month report. J Vasc Surg. 2004 Jun; 39 [6]: 1268-76.
27. Keeling AN, Naughton PA, O'Connell A, Lee MJ. Does percutaneous trans-luminal angioplasty improve quality of life? J Vasc Interv Radiol. 2008 Feb; 19 [2 Pt 1]: 169-76.
28. Klevsgard R, Froberg BL, Risberg B, Hallberg IR. Nottingham Health Profile and Short-Form 36 Health Survey questionnaires in patients with chronic lower limb ischemia: before and after revascularization. J Vasc Surg. 2002 Aug; 36 [2]: 310-7.
29. Klevsgard R, Hallberg IR, Risberg B, Thomsen MB. Quality of life associated with varying degrees of chronic lower limb ischaemia: comparison with a healthy sample. Eur J Vasc Endovasc Surg. 1999 Apr; 17 [4]: 319-25.
30. Klevsgard R, Risberg BO, Thomsen MB, Hallberg IR. A 1-year follow- up quality of life study after hemodynamically successful or unsuccessful surgical revascularization of lower limb ischemia. J Vasc Surg. 2001 Jan; 33 [1]: 114-22.
31. Mangiafico RA, Messina R, Attina T, Dell'Arte S, Giuliano L, Malatino LS. Impact of a 4-week treatment with prostaglandin E1 on health-related quality of life of patients with intermittent claudication. Angiology. 2000 Jun; 51 [6]: 441-9.
32. Marquis P, Comte S, Lehert P. Inter- national validation of the CLAU-S quality-of-life questionnaire for use in patients with intermittent claudication. Pharmacoeconomics. 2001; 19 [6]: 667-77.
33. Martem'ianov SV, Uvarov EA, Safonova OV. Assessment of the patient's quality of life in the longterm postoperative period after re-constructions on lower extremity arteries. Angiol Sosud Khir. 2004; 10 [2]: 129-35.
34. Matoba S, Matsubara H. Therapeutic angiogenesis for peripheral artery diseases by autologous bone marrow cell transplantation. Curr Pharm Des. 2009; 15 [24]: 2769-77.
35. Maulik N. NV1FGF, a pCOR plasmid-based angiogenic gene therapy for the treatment of intermittent claudication and critical limb ischemia. Curr Opin Investig Drugs. 2009 Mar; 10 [3]: 259-68.
36. McHorney CA, Ware JE, Jr., Lu JF, Sherbourne CD. The MOS 36-item Short-Form Health Survey [SF-36]: III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care. 1994 Jan; 32 [1]: 40-66.
37. McHorney CA, Ware JE, Jr., Raczek AE. The MOS 36-Item Short-Form Health Survey [SF-36]: II. Psycho- metric and clinical tests of validity in measuring physical and mental health constructs. Med Care. 1993 Mar; 31 [3]: 247-63.
38. Melillo E, Nuti M, Buttitta F, Balbarini A. [Medical therapy in critical lower limb ischemia when immediate revascularization is not feasible]. G Ital Cardiol [Rome]. 2006 May; 7 [5]: 317-35.
39. Met R, Reekers JA, Koelemay MJ, Legemate DA, de Haan RJ. The AMC linear disability score [ALDS]: a cross-sectional study with a new generic instrument to measure disability applied to patients with peripheral arterial disease. Health Qual Life Outcomes. 2009; 7: 88.
40. Morgan MB, Crayford T, Murrin B, Fraser SC. Developing the Vascular Quality of Life Questionnaire: a new disease-specific quality of life measure for use in lower limb ischemia. J Vasc Surg. 2001 Apr; 33 [4]: 679-87.
41. Murphy MC, Steele CM, Gross JJ. Signaling threat: how situational cues affect women in math, science, and engineering settings. Psychol Sci. 2007 Oct; 18 [10]: 879-85.
42. Murphy MP, Lawson JH, Rapp BM, Dalsing MC, Klein J, Wilson MG, Hutchins GD, March KL. Autologous bone marrow mononuclear cell therapy is safe and promotes amputation-free survival in patients with critical limb ischemia. J Vasc Surg. 2011 Jun; 53 [6]: 1565-74 e1.
43. Murphy TP. Medical outcomes studies in peripheral vascular disease. J Vasc Interv Radiol. 1998 Nov-Dec; 9 [6]: 879-89.
44. Nguyen LL, Brahmanandam S, Bandyk DF, Belkin M, Clowes AW, Moneta GL, Conte MS. Female gender and oral anticoagulants are as- sociated with wound complications in lower extremity vein bypass: an analysis of 1404 operations for critical limb ischemia. J Vasc Surg. 2007 Dec; 46 [6]: 1191-7.
45. Nguyen LL, Moneta GL, Conte MS, Bandyk DF, Clowes AW, Seely BL. Prospective multicenter study of quality of life before and after lower extremity vein bypass in 1404 patients with critical limb ischemia. J Vasc Surg. 2006 Nov; 44 [5]: 977-83; discussion 83-4.
46. Nikol S, Baumgartner I, Van Belle E, Diehm C, Visona A, Capogrossi MC, Ferreira-Maldent N, Gallino A, Wyatt MG, Wijesinghe LD, Fusari M, Stephan D, Emmerich J, Pompilio G, Vermassen F, Pham E, Grek V, Coleman M, Meyer F. Therapeutic angiogenesis with intramuscular NV1FGF improves amputation-free survival in patients with critical limb ischemia. Mol Ther. 2008 May; 16 [5]: 972-8.
47. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG, Bell K, Caporusso J, Durand-Zaleski I, Komori K, Lammer J, Liapis C, Novo S, Razavi M, Robbs J, Schaper N, Shigematsu H, Sapoval M, White C, White J. Inter-Society Consensus for the Management of Peripheral Arterial Disease [TASC II]. Eur J Vasc Endovasc Surg. 2007; 33 Suppl 1:S1-75.
48. Perin EC, Silva G, Gahremanpour A, Canales J, Zheng Y, Cabreira-Hansen MG, Mendelsohn F, Chro-nos N, Haley R, Willerson JT, Annex BH. A randomized, controlled study of autologous therapy with bone marrow-derived aldehyde dehydrogenase bright cells in patients with critical limb ischemia. Catheter Cardiovasc Interv. 2011 May 18.
49. Powell RJ, Dormandy J, Simons M, Morishita R, Annex BH. Therapeutic angiogenesis for critical limb ischemia: design of the hepatocyte growth factor therapeutic angiogenesis clinical trial. Vasc Med. 2004 May; 9 [3]: 193-8.
50. Regensteiner JG, Hiatt WR, Coll JR, Criqui MH, Treat-Jacobson D, Mc-Dermott MM, Hirsch AT. The impact of peripheral arterial disease on health-related quality of life in the Peripheral Arterial Disease Awareness, Risk, and Treatment: New Re-sources for Survival [PARTNERS] Program. Vasc Med. 2008 Feb; 13 [1]: 15-24.
51. Silvestro A, Bacchieri A, Bucur R, Di Donato AM, Costantino C, Corrado S, Brevetti G. [A new questionnaire for assessing the quality of life of patients with intermittent claudication]. Minerva Cardioan-giol. 2000 Dec; 48 [12]: 455-65.
52. Simons PC, Algra A, van de Laak MF, Grobbee DE, van der Graaf Y. Second manifestations of ARTerial disease [SMART] study: rationale and design. Eur J Epidemiol. 1999 Oct; 15 [9]: 773-81.
53. Spengel FA, Lehert P, Dietze S. A statistical consideration of CLAU- S: a disease specific questionnaire for the assessment of quality of life in patients with intermittent claudication. Vasa. 1998 Nov; 27 [4]: 253.
54. Sprengers RW, Moll FL, Teraa M, Verhaar MC. Rationale and design of the JUVENTAS trial for repeated intra-arterial infusion of autologous bone marrow-derived mononuclear cells in patients with critical limb ischemia. J Vasc Surg. 2010 Jun; 51 [6]: 1564-8.
55. Sprengers RW, Teraa M, Moll FL, de Wit GA, van der Graaf Y, Verhaar MC. Quality of life in patients with no-option critical limb ischemia underlines the need for new effective treatment. J Vasc Surg. 2010 Oct; 52 [4]: 843-9, 9 e1.
56. Stiegler H, Bullinger M, Cachovan M, Creutzig A, Diehm C, Gruß J, Heidrich H, Horsch S, Rogatti W, Spengel FA. Multizentrische Studie zur Lebensqualität nach v. Prostavasin-Therapie im Stadium IV der AVK. VASA. 1999; 54: 20-6.
57. Thorsen H, McKenna S, Tennant A, Holstein P. Nottingham health profile scores predict the outcome and support aggressive revascularisation for critical ischaemia. Eur J Vasc Endovasc Surg. 2002 Jun; 23 [6]: 495-9.
58. Thorsen H, McKenna SP, Gott-schalck L. The Danish version of the Nottingham Health Profile: its adaptation and reliability. Scand J Prim Health Care. 1993 Jun; 11 [2]: 124-9.
59. Thorsen H, McKenna SP, Gott-schalck L. Perceived health in three groups of elderly people. A validity study of the Danish version of the Nottingham Health Profile. Dan Med Bull. 1995 Feb; 42[1]: 105-8.
60. Tretinyak AS, Lee ES, Kuskowski MM, Caldwell MP, Santilli SM. Revascularization and quality of life for patients with limb-threatening ischemia. Ann Vasc Surg. 2001 Jan; 15 [1]: 84-8.
61. Virkkunen J, Venermo M, Saarinen J, Keski-Nisula L, Apuli P, Kankain- en AL, Salenius J. Impact of endovascular treatment on clinical status and health-related quality of life. Scand J Surg. 2008; 97 [1]: 50-5.
62. Wann-Hansson C, Hallberg IR, Ris-berg B, Klevsgard R. A comparison of the Nottingham Health Profile and Short Form 36 Health Survey in patients with chronic lower limb ischaemia in a longitudinal perspective. Health Qual Life Outcomes. 2004 Feb 17; 2: 9.
63. Wann-Hansson C, Hallberg IR, Risberg B, Lundell A, Klevsgard R. Health-related quality of life after revascularization for peripheral arterial occlusive disease: long-term follow-up. J Adv Nurs. 2005 Aug; 51 [3]: 227-35.
64. Ware JE, Jr. SF-36 health survey update. Spine [Phila Pa 1976]. 2000 Dec 15; 25 [24]: 3130-9.
65. Ware JE, Jr., Sherbourne CD. The MOS 36-item short-form health survey [SF-36]. I. Conceptual framework and item selection. Med Care. 1992 Jun; 30 [6]: 473-83.
66. Wohlgemuth WA, Olbricht W, Klar- mann S, Engelhardt M, Freitag MH, Wolfle K, Bohndorf K, Kirchhof K. [Disease-specific Questionnaire for Quality of Life in Patients with Peripheral Arterial Occlusive Disease in the Stage of Critical Ischemia [FLeQKI]--methodical development of a specific measuring instrument and psychometric evaluation of its validity and reliability [Part 1]]. Rofo. 2007 Dec; 179 [12]: 1251-7.
67. Wohlgemuth WA, Olbricht W, Klar- mann S, Engelhardt M, Freitag MH, Wolfle K, Bohndorf K, Kirchhof K. [Disease-specific Questionnaire for Quality of Life in Patients with Peripheral Arterial Occlusive Disease in the Stage of Critical Ischemia [FLeQKI]: psychometric evaluation of its responsiveness and practicability [Part 2]]. Rofo. 2007 Dec; 179 [12]: 1258-63.